Costs of care associated with non-small-cell lung cancer in a commercially insured cohort

被引:45
作者
Hillner, BE
McDonald, MK
Desch, CE
Smith, TJ
Penberthy, LT
Maddox, P
Retchin, SM
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Dept Internal Med, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA
[3] Trigon Blue Cross Blue Shield, Richmond, VA USA
关键词
D O I
10.1200/JCO.1998.16.4.1420
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To examine the cost of incident cases of non-small-cell lung cancer (NSCLC) in a commercially insured cohort. Methods: Claims from Virginia Blue Cross and Blue Shield (BCBS) beneficiaries with lung cancer from 1989 to 1991 were merged with records from the Virginia Cancer Registry (VCR). Data from the VCR identified incident cases, stage, and type of cancer at diagnosis, Costs for all medical care included insurance payment, copayments, and deductibles for 2 years after diagnosis or until death. Results: Three hundred forty-nine incident NSCLC patients were evaluated. The mean 9-year cost for each patient after diagnosis or until death was $47,941 (95% confidence interval, $43,758 to $52,124). Total average costs and hospital days were significantly lower for local disease ($37,514, 21.2 days), but were similar for regional ($52,797, 30.0 days) and distant ($49,382, 33.0 days) disease. Hospital days accounted for 48% and hospital-based claims for 70% of costs. Initial treatments, which included radiation, unadjusted for stage, had the lowest survival rates and the highest costs, and were associated with the most hospital days. Initial stage, race, gender, and age were not predictors of total 5-year costs, The independent predictors of total 5-year costs were type of treatment: any radiation therapy, any surgery, or any chemotherapy (all, P < .001). Inpatient hospital days was only a modest predictor of costs after adjusting for type of treatment. Patients who survived less than 1 year spent 30.5 days in hospital and had an average cost of $47,280. Conclusion: The direct health care costs of younger NSCLC patients care are substantial, These results should serve as a benchmark for future comparisons as the United States market shifts to managed care. (C) 1998 by American Society of Clinical Oncology.
引用
收藏
页码:1420 / 1424
页数:5
相关论文
共 13 条
  • [1] ALBERTI W, 1995, BRIT MED J, V311, P899
  • [2] DEVELOPMENT OF CLINICAL AND ECONOMIC PROGNOSES FROM MEDICARE CLAIMS DATA
    ANDERSON, G
    STEINBERG, EP
    WHITTLE, J
    POWE, NR
    ANTEBI, S
    HERBERT, R
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (07): : 967 - 972
  • [3] EVALUATION OF DIRECT MEDICAL COSTS RELATED TO CANCER
    BROWN, ML
    FIREMAN, B
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (06) : 399 - 400
  • [4] Factors that determine the treatment for local and regional prostate cancer
    Desch, CE
    Penberthy, L
    Newschaffer, CJ
    Hillner, BE
    Whittemore, M
    McClish, D
    Smith, TJ
    Retchin, SM
    [J]. MEDICAL CARE, 1996, 34 (02) : 152 - 162
  • [5] The economics of lung cancer management in Canada
    Evans, WK
    Will, BP
    Berthelot, JM
    Wolfson, MC
    [J]. LUNG CANCER, 1996, 14 (01) : 19 - 29
  • [6] DIAGNOSTIC AND THERAPEUTIC APPROACHES TO LUNG-CANCER IN CANADA AND THEIR COSTS
    EVANS, WK
    WILL, BP
    BERTHELOT, JM
    WOLFSON, MC
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (05) : 1270 - 1277
  • [7] Fry WA, 1996, CANCER, V77, P1947, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1947::AID-CNCR27>3.0.CO
  • [8] 2-Z
  • [9] Measuring standards of care for early breast cancer in an insured population
    Hillner, BE
    McDonald, MK
    Penberthy, L
    Desch, CE
    Smith, TJ
    Maddux, P
    Glasheen, WP
    Retchin, SM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) : 1401 - 1408
  • [10] Parente S T, 1995, Am J Med Qual, V10, P162, DOI 10.1177/0885713X9501000402